ARTICLE | Finance
RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies
With a $105 million series B, the radiopharmaceuticals platform newco can pursue multiple programs in parallel
December 12, 2020 1:48 AM UTC
Encountering unanticipated investor interest after closing its series A round, RayzeBio followed up two months later with a series B raise that triples its reserves and frees the platform company from the need to make trade-offs between pipeline programs.
The company’s quick jump from a $45 million series A round Oct. 14 to $105 million series B round Dec. 8 reflects growing enthusiasm for targeted radiotherapies. Once left for dead, the field has been revived by clinical and commercial success, including a handful of ten-figure takeouts...
BCIQ Company Profiles